Cargando…

Pitfalls in diagnosis with the use of circulating tumor‐derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M

The circulating tumor DNA (ctDNA) assay has recently been approved for the selection of EGFR‐tyrosine kinase inhibitors as first‐line treatment in lung cancer. However, it remains to be determined whether this assay can detect all complex EGFR mutations within a single tumor. We report a case of an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogawara, Daiki, Soda, Hiroshi, Suyama, Takayuki, Yoshida, Masataka, Harada, Tatsuhiko, Fukuda, Yuichi, Mukae, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2017
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754312/ https://www.ncbi.nlm.nih.gov/pubmed/29063709 http://dx.doi.org/10.1111/1759-7714.12538

Ejemplares similares

Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab
por: Okamura, Kazuaki, et al.
Publicado: (2017)

Successful treatment with nivolumab for lung cancer with low expression of PD‐L1 and prominent tumor‐infiltrating B cells and immunoglobulin G
por: Suyama, Takayuki, et al.
Publicado: (2018)

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
por: Ogawara, Daiki, et al.
Publicado: (2017)

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study
por: Soda, Hiroshi, et al.
Publicado: (2018)

Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient
por: Ogawara, Daiki, et al.
Publicado: (2017)

Pulmonary Artery Sarcoma Overexpressing Platelet-derived Growth Factor Receptor α
por: Takemoto, Shinnosuke, et al.
Publicado: (2017)

Presence of few PD‐1‐expressing tumor‐infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non‐small cell lung cancer: An exploratory case series
por: Ogawara, Daiki, et al.
Publicado: (2018)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
por: Yamaguchi, Ou, et al.
Publicado: (2023)

Alert Regarding Cisplatin-induced Severe Adverse Events in Cancer Patients with Xeroderma Pigmentosum
por: Sumiyoshi, Makoto, et al.
Publicado: (2017)

Vildagliptin‐induced ground‐glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation
por: Tanaka, Yasuhiro, et al.
Publicado: (2020)

Exploring the ethical complexities of do‐not‐attempt‐resuscitation orders using the approach of advance care planning
por: Ogata, Ryo, et al.
Publicado: (2023)

Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation
por: Dotsu, Yosuke, et al.
Publicado: (2020)

Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis
por: Takemoto, Shinnosuke, et al.
Publicado: (2021)

Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia‐inducible factor‐1α, vascular endothelial growth factor, and hypervascularization
por: Tagawa, Ryuta, et al.
Publicado: (2023)

Incidental diagnosis of pulmonary cryptococcosis by rebiopsy for epidermal growth factor receptor T790M mutation: A case report
por: Kobe, Hiroshi, et al.
Publicado: (2022)

Onset of pulmonary Epstein–Barr virus‐positive diffuse large B‐cell lymphoma in a patient with silicosis
por: Ogata, Ryosuke, et al.
Publicado: (2021)

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports
por: Koba, Taro, et al.
Publicado: (2017)

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report
por: WANG, YUE FENG, et al.
Publicado: (2014)

Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
por: Yamane, Hiromichi, et al.
Publicado: (2013)

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016)

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
por: Tanaka, Kentaro, et al.
Publicado: (2017)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
por: Odogwu, Lauretta, et al.
Publicado: (2017)

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Hu, Shanliang, et al.
Publicado: (2022)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

Intrathoracic amyloid tumors that presented as yellowish multinodular endobronchial protrusions with irregular vascularity and easy bleeding
por: Tomono, Hiromi, et al.
Publicado: (2019)

Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment
por: Chikaishi, Yasuhiro, et al.
Publicado: (2014)

The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2017)

Phase II trial of a non‐platinum triplet for patients with advanced non‐small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
por: Dotsu, Yosuke, et al.
Publicado: (2021)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Primary Mediastinal Large B-cell Lymphoma Exhibiting Endobronchial Involvement
por: Shimada, Midori, et al.
Publicado: (2016)

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
por: Lategahn, Jonas, et al.
Publicado: (2019)

Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report
por: Nishioka, Naoya, et al.
Publicado: (2018)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
por: Niu, Hardy, et al.
Publicado: (2017)

Unusual metachronous lung adenocarcinomas harboring EGFR L858R/T790M mutations: A case report
por: Pei, Guotian, et al.
Publicado: (2020)

Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
por: Nishiya, Naoyuki, et al.
Publicado: (2021)

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
por: Carter, Corey A., et al.
Publicado: (2016)

Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
por: Park, Mi-Young, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ng6okhcfvdb4h296iuhicse250